We have tested the cytolytic capacity of such patient-derived PBMCs and found that the CD8+CD56+ cells accumulating upon treatment are able to kill autologous (but not allogeneic) cancer cells (manuscript in preparation). This evidence concerns the gene CD8A and cancer.